PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27565148-8 2016 Notably, lovastatin normalized impaired LTP-like plasticity and increased intracortical inhibition in patients with NF1. Lovastatin 9-19 neurofibromin 1 Homo sapiens 116-119 27956565-0 2016 Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Lovastatin 39-49 neurofibromin 1 Homo sapiens 67-91 32022434-4 2020 We leveraged a large, international cognitive study in affected children with NF1 treated with lovastatin to assess spatial learning using the "Arena Maze", a portable, computerized task that allows for retesting in the same environment. Lovastatin 95-105 neurofibromin 1 Homo sapiens 78-81 27956565-1 2016 OBJECTIVE: To assess the efficacy of lovastatin on visuospatial learning and attention for treating cognitive and behavioral deficits in children with neurofibromatosis type 1 (NF1). Lovastatin 37-47 neurofibromin 1 Homo sapiens 151-175 27956565-1 2016 OBJECTIVE: To assess the efficacy of lovastatin on visuospatial learning and attention for treating cognitive and behavioral deficits in children with neurofibromatosis type 1 (NF1). Lovastatin 37-47 neurofibromin 1 Homo sapiens 177-180 27956565-12 2016 CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for children with NF1, lovastatin does not improve visuospatial learning or attention deficits. Lovastatin 93-103 neurofibromin 1 Homo sapiens 88-91 22433254-0 2012 Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1. Lovastatin 0-10 neurofibromin 1 Homo sapiens 71-95 24088225-0 2013 Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1. Lovastatin 0-10 neurofibromin 1 Homo sapiens 87-111 27081657-2 2016 We conducted a randomized double-blind placebo-controlled trial to assess lovastatin"s effects on cognition and behavior in patients with NF1. Lovastatin 74-84 neurofibromin 1 Homo sapiens 138-141 27081657-12 2016 INTERPRETATION: These preliminary results suggest beneficial effects of lovastatin on some learning and memory functions, as well as internalizing symptoms in patients with NF1. Lovastatin 72-82 neurofibromin 1 Homo sapiens 173-176 26562280-3 2015 The advent of new treatment options for NF1 such as topical vitamin D3 analogues, lovastatin, rapamycin (or sirolimus), and imatinib mesylate has added new dimensions that require further investigation to provide the greatest benefit to patients. Lovastatin 82-92 neurofibromin 1 Homo sapiens 40-43 24088225-8 2013 RESULTS: In patients with NF1, lovastatin revealed significant decrease of intracortical inhibition, significant increase of synaptic plasticity as well as significant increase of phasic alertness. Lovastatin 31-41 neurofibromin 1 Homo sapiens 26-29 24088225-11 2013 Our findings revealed mechanisms of attention disorders in humans with NF1 and support the idea of a potential clinical benefit of lovastatin as a therapeutic option. Lovastatin 131-141 neurofibromin 1 Homo sapiens 71-74 22433254-4 2012 Seven children with NF1 (aged 11.9 +- 2.2; 1 female) were treated with lovastatin once daily for 12 weeks. Lovastatin 71-81 neurofibromin 1 Homo sapiens 20-23 21850405-7 2011 A clinical trial is under way to evaluate lovastatin in the treatment of cognitive problems in children with NF1. Lovastatin 42-52 neurofibromin 1 Homo sapiens 109-112 20200958-9 2010 These results thus indicate that the dysfunctions caused by loss of Nf1 in osteoblasts impair callus maturation and weaken callus mechanical properties and suggest that local delivery of low-dose lovastatin may improve bone healing in NF1 patients. Lovastatin 196-206 neurofibromin 1 Homo sapiens 68-71 20200958-9 2010 These results thus indicate that the dysfunctions caused by loss of Nf1 in osteoblasts impair callus maturation and weaken callus mechanical properties and suggest that local delivery of low-dose lovastatin may improve bone healing in NF1 patients. Lovastatin 196-206 neurofibromin 1 Homo sapiens 235-238 21907886-0 2011 Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Lovastatin 0-10 neurofibromin 1 Homo sapiens 55-79 21907886-1 2011 In a neurofibromatosis type 1 murine model, treatment with lovastatin reversed cognitive disabilities. Lovastatin 59-69 neurofibromin 1 Homo sapiens 5-29 21907886-2 2011 We report on a phase I study examining the safety and tolerability of lovastatin in children with neurofibromatosis type 1. Lovastatin 70-80 neurofibromin 1 Homo sapiens 98-122 21907886-7 2011 These observations may be analogous to the improvements observed in a neurofibromatosis type 1 murine model treated with lovastatin, although further study and replication are required. Lovastatin 121-131 neurofibromin 1 Homo sapiens 70-94